Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor receptor type 1-associated death domain protein (TRADD) is a vital adapter molecule in the TNF-alpha signaling pathway, serving as a scaffold for both pro-survival NF-kappaB activation and pro-death apoptotic or necroptotic signaling (Source: UniProt P46531). The 3' untranslated region (3'UTR) of TRADD mRNA contains regulatory sequences that determine the stability and translation of the transcript, making it a strategic target for RNA-based therapeutics (Source: PubMed 22438544). Antisense oligonucleotides (ASOs) designed to hybridize with the TRADD mRNA 3'UTR can trigger RNase H-mediated degradation, effectively lowering TRADD protein levels and dampening TNF-induced inflammation and cell death (Source: PubMed 26133978). This target is of significant interest in treating chronic inflammatory diseases like psoriasis and neurodegenerative conditions such as Amyotrophic Lateral Sclerosis (ALS), where TRADD-mediated necroptosis contributes to disease progression (Source: PubMed 28842572). Experimental studies have demonstrated that reducing TRADD expression via 3'UTR-targeted ASOs can protect against systemic inflammatory response syndrome and localized tissue damage in animal models (Source: PubMed 26133978). By specifically targeting the 3'UTR, researchers can achieve potent knockdown of the TRADD protein, providing a therapeutic window to modulate TNF-mediated pathologies without completely abolishing the immune response.
Antisense oligonucleotides bind to the 3'UTR of TRADD mRNA, leading to RNase H-mediated degradation of the transcript and subsequent reduction in TRADD protein synthesis.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor receptor type 1-associated death domain protein mRNA 3' untranslated region (TRADD mRNA 3'UTR) (TRADD mRNA 3'UTR).